RxDoctor Payments Data

Edward Kepp, MD

Internal Medicine · Albemarle, NCNPI 1194785899

Payments from drug & device makers

$4,405in general payments, 2019–2025

Across 290 payments — averaging $15.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$645
  • AstraZeneca$593
  • Pfizer$478
  • Novo Nordisk$468
  • AbbVie$374
  • Lilly USA, LLC$342
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$4,405100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,405 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$54,650
Medicare patients
148
Services billed
561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban182$135,090
JardianceEmpagliflozin121$101,985
OzempicSemaglutide84$97,570
FarxigaDapagliflozin Propanediol91$57,972
MounjaroTirzepatide44$45,028
KerendiaFinerenone47$38,247
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$28,503
MyrbetriqMirabegron42$26,579
Humalog Kwikpen U-200Insulin Lispro11$21,941
XareltoRivaroxaban25$17,897
Gvoke Hypopen 2-PackGlucagon12$13,226
Spiriva HandihalerTiotropium Bromide15$12,668
NexlizetBempedoic Acid/Ezetimibe20$11,692
Lantus SolostarInsulin Glargine,hum.Rec.Anlog62$11,149
VascepaIcosapent Ethyl17$9,983

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$478$135,090182 claims
Boehringer IngelheimJardiance$216$101,985121 claims
Novo NordiskOzempic$468$97,57084 claims
AstraZenecaFarxiga, Breztri Aerosphere$593$67,512106 claims
Lilly USA, LLCMounjaro$342$45,02844 claims
BayerKerendia$645$38,24747 claims
GSKTrelegy Ellipta, Breo Ellipta$17$34,26253 claims
Johnson & JohnsonXarelto$11$17,89725 claims
Esperion Therapeutics, Inc.Nexlizet$80$11,69220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Albemarle

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →